Panelists discuss how a woman aged 55 years with T3N1M0 locally advanced squamous cell carcinoma represents a typical case for definitive chemoradiation therapy over surgical resection, emphasizing the importance of supportive care measures, including pain management, hydration monitoring, and patient education, to optimize treatment completion rates and minimize toxicity.
July marks a transformative month in oncology with the FDA’s groundbreaking approvals and updates, enhancing treatment options for various cancers.
In our first episode of Treating Together, Benjamin Garmezy, MD, and Ralph J. Miller Jr, MD, discuss multidisciplinary prostate cancer care.
Pirtobrutinib shows promising results in treating CLL, outperforming ibrutinib in a pivotal phase 3 trial, paving the way for broader applications.
MAIA Biotechnology’s ateganosine gains FDA fast track status, offering hope for advanced NSCLC patients with limited treatment options.
Durvalumab’s breakthrough therapy designation offers hope for improved outcomes in early-stage gastric and GEJ cancers, potentially transforming treatment strategies.
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.
The EU approves belantamab mafodotin combinations, enhancing treatment options for relapsed multiple myeloma patients with promising efficacy and safety profiles.
Benjamin Schlechter, MD, discusses the unmet needs and treatment gaps for patients with colorectal cancer.
New findings confirm that partial-breast and reduced-dose radiotherapy effectively treat low-risk early-stage breast cancer with fewer side effects.
FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved survival rates for patients.
